Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1

Cohesin is a multi-protein complex that tethers sister chromatids during mitosis and mediates DNA repair, genome compartmentalisation and regulation of gene expression. Cohesin subunits frequently acquire cancer loss-of-function alterations and act as tumour suppressors in several tumour types. This has led to increased interest in cohesin as potential target in anti-cancer therapy. Here we show that the loss-of-function of STAG2, a core component of cohesin and an emerging tumour suppressor, leads to synthetic dependency of mutated cancer cells on its paralog STAG1. STAG1 and STAG2 share high sequence identity, encode mutually exclusive cohesin subunits and retain partially overlapping functions. We inhibited STAG1 and STAG2 in several cancer cell lines where the two genes have variable mutation and copy number status. In all cases, we observed that the simultaneous blocking of STAG1 and STAG2 significantly reduces cell proliferation. We further confirmed the synthetic lethal interaction developing a vector-free CRISPR system to induce STAG1/STAG2 double gene knockout. We provide strong evidence that STAG1 is a promising therapeutic target in cancers with inactivating alterations of STAG2.

[1]  Sanjeeva Srivastava,et al.  Cohesin: Functions beyond sister chromatid cohesion , 2013, FEBS letters.

[2]  Peer Bork,et al.  SMART: recent updates, new developments and status in 2015 , 2014, Nucleic Acids Res..

[3]  F. Ciccarelli,et al.  Genetic Redundancy, Functional Compensation, and Cancer Vulnerability. , 2016, Trends in cancer.

[4]  Hongtao Yu,et al.  Mutational Inactivation of STAG2 Causes Aneuploidy in Human Cancer , 2011, Science.

[5]  M. Berns,et al.  Distinct Functions of Human Cohesin-SA1 and Cohesin-SA2 in Double-Strand Break Repair , 2013, Molecular and Cellular Biology.

[6]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[7]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[8]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[9]  Tom R. Gaunt,et al.  Predicting the functional consequences of cancer-associated amino acid substitutions , 2013, Bioinform..

[10]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[11]  M. Leverkus,et al.  Crystal Violet Assay for Determining Viability of Cultured Cells. , 2016, Cold Spring Harbor protocols.

[12]  A. Kawahara,et al.  Efficient Multiple Genome Modifications Induced by the crRNAs, tracrRNA and Cas9 Protein Complex in Zebrafish , 2015, PloS one.

[13]  Andrew W. Folkmann,et al.  High Efficiency, Homology-Directed Genome Editing in Caenorhabditis elegans Using CRISPR-Cas9 Ribonucleoprotein Complexes , 2015, Genetics.

[14]  Xiaohui Xie,et al.  Identifying novel constrained elements by exploiting biased substitution patterns , 2009, Bioinform..

[15]  Abbas Shirinifard,et al.  Targeting the DNA repair pathway in Ewing sarcoma. , 2014, Cell reports.

[16]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[17]  R. Sullivan,et al.  Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma , 2016, Nature Medicine.

[18]  A. Valencia,et al.  Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy , 2013, Nature Genetics.

[19]  Takashi Yamamoto,et al.  Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice , 2015, Genome Biology.

[20]  Namritha Ravinder,et al.  Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. , 2015, Journal of biotechnology.

[21]  Kim Nasmyth,et al.  Cohesin: its roles and mechanisms. , 2009, Annual review of genetics.

[22]  M. Blasco,et al.  Cohesin‐SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres , 2012, The EMBO journal.

[23]  F. Ciccarelli,et al.  Recessive cancer genes engage in negative genetic interactions with their functional paralogs. , 2013, Cell reports.

[24]  W. Hahn,et al.  ARID1B is a specific vulnerability in ARID1A-mutant cancers , 2014, Nature Medicine.

[25]  Eric Boerwinkle,et al.  In silico prediction of splice-altering single nucleotide variants in the human genome , 2014, Nucleic acids research.

[26]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[27]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[28]  Parantu K. Shah,et al.  The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. , 2015, Cancer research.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[30]  M. Rubin,et al.  Frequent truncating mutations of STAG2 in bladder cancer , 2013, Nature Genetics.

[31]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[32]  Francesca D. Ciccarelli,et al.  NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings , 2015, Nucleic Acids Res..

[33]  Julia C. Engelmann,et al.  Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. , 2012, Blood.

[34]  G. Mufti,et al.  Applying synthetic lethality for the selective targeting of cancer. , 2014, The New England journal of medicine.

[35]  Serafim Batzoglou,et al.  Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..

[36]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[37]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[38]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[39]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[40]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[41]  J. Peters,et al.  Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2 , 2016, PLoS genetics.

[42]  Jana Marie Schwarz,et al.  MutationTaster evaluates disease-causing potential of sequence alterations , 2010, Nature Methods.

[43]  M. Stratton,et al.  RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia , 2014, Nature Genetics.

[44]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[45]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[46]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[47]  A. Losada,et al.  Cohesin in cancer: chromosome segregation and beyond , 2014, Nature Reviews Cancer.

[48]  Justin C. Fay,et al.  Identification of deleterious mutations within three human genomes. , 2009, Genome research.

[49]  P. Hieter,et al.  Synthetic lethality and cancer: cohesin and PARP at the replication fork. , 2013, Trends in genetics : TIG.

[50]  C. Sander,et al.  Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.

[51]  R. Wolthuis,et al.  Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function , 2015, Nature Communications.

[52]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[53]  K. Nasmyth,et al.  The cohesin ring concatenates sister DNA molecules , 2008, Nature.

[54]  C. Roberts,et al.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.

[55]  J. Yokota,et al.  A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. , 2013, Cancer research.

[56]  P. Hieter,et al.  Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators , 2012, PLoS genetics.

[57]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[58]  Xiquan Liang,et al.  Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX , 2016, Biotechnology Letters.

[59]  P. Hieter,et al.  Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition , 2013, Molecular Cancer Therapeutics.

[60]  Z. Strezoska,et al.  Systematic analysis of CRISPR-Cas9 mismatch tolerance reveals low levels of off-target activity. , 2015, Journal of biotechnology.

[61]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[62]  Masao Nagasaki,et al.  Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms , 2012, Nature Genetics.

[63]  K. Pollard,et al.  Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.

[64]  Susan Smith,et al.  Differential regulation of telomere and centromere cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells , 2009, The Journal of cell biology.